It is made available under a CC-BY-NC-ND 4.0 International license .

### Salivary Biomarkers as Pioneering Indicators for Diagnosis and Severity Stratification of Pediatric Long COVID

3

Sylwia D. Tyrkalska<sup>1,2,3,#</sup>, Fernando Pérez-Sanz<sup>2,#</sup>, Lorena Franco-Martínez<sup>4</sup>, Camila PeresRubio<sup>4</sup>, Asta Tvarijonaviciute<sup>4</sup>, Silvia Martínez-Subiela<sup>4</sup>, María Méndez-Hernández<sup>5,6</sup>, Alba
González-Aumatell<sup>5,6</sup>, Clara Carreras-Abad<sup>5,6</sup>, Èlia Domènech-Marçal<sup>5,6</sup>, José J. Cerón<sup>4</sup>, María L.
Cayuela<sup>2,3,7,\*</sup>, Victoriano Mulero<sup>1,2,3,\*</sup>, Sergio Candel<sup>1,2,3,\*</sup>

8

<sup>1</sup>Grupo de Inmunidad, Inflamación y Cáncer, Departamento de Biología Celular e Histología,
Facultad de Biología, Universidad de Murcia, 30100 Murcia, Spain.

<sup>2</sup>Instituto Murciano de Investigación Biosanitaria (IMIB)-Pascual Parrilla, 30120 Murcia, Spain.

<sup>3</sup>Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de
 Salud Carlos III, 28029 Madrid, Spain.

<sup>4</sup>Laboratorio Interdisciplinar de Análisis Clínicos, Campus Mare Nostrum, Facultad de
 Veterinaria, Universidad de Murcia (Interlab-UMU), 30100 Murcia, Spain.

<sup>5</sup>Unidad de Covid Persistente Pediátrico. Servicio de Pediatría, Hospital Universitario Germans
Trias i Pujol, 08916 Badalona, Spain.

<sup>6</sup>Departamento de Pediatría, Obstetricia y Ginecología, Medicina Preventiva y Salud Pública,

19 Facultad de Medicina, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, España.

<sup>7</sup>Grupo de Telomerasa, Cáncer y Envejecimiento, Servicio de Cirugía, Hospital Clínico
Universitario Virgen de la Arrixaca, 30120 Murcia, Spain.

22

<sup>#</sup>These authors contributed equally.

\*To whom correspondence should be sent at: <u>marial.cayuela@carm.es</u> (MLC), <u>vmulero@um.es</u>

 $25 \quad (VM), \underline{scandel@um.es} (SC).$ 

26

It is made available under a CC-BY-NC-ND 4.0 International license .

### 27 ABSTRACT

Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), manifests as 28 persistent and often debilitating symptoms enduring well beyond the initial COVID-19 infection. 29 Presently, a specific diagnostic test or definitive biomarker set for confirming long COVID is 30 31 lacking, relying instead on the protracted presence of symptoms post-acute infection. In this study, we examined 105 saliva samples (49 from children with long COVID and 56 controls), revealing 32 significant alterations in salivary biomarkers. Pediatric long COVID exhibited increased oxidant 33 biomarkers, decreased antioxidant, immune response, and stress-related biomarkers. Correlation 34 35 analyses unveiled distinct patterns between biomarkers in long COVID and controls. Notably, a 36 multivariate logistic regression pinpointed TOS, ADA2, total proteins, and AOPP as pivotal variables, culminating in a remarkably accurate predictive model distinguishing long COVID from 37 38 controls. Furthermore, total proteins and ADA1 were instrumental in discerning between mild and severe long COVID symptoms. This research sheds light on the potential clinical utility of salivary 39 40 biomarkers in diagnosing and categorizing the severity of pediatric long COVID. It also lays the groundwork for future investigations aimed at unraveling the prognostic value of these biomarkers 41 in predicting the trajectory of long COVID in affected individuals. 42

- 43
- 44

45 Keywords: Pediatric long COVID, Salivary biomarkers, Predictive models, Bioinformatics.

46

47

48

49

It is made available under a CC-BY-NC-ND 4.0 International license .

### 50 INTRODUCTION

The novel betacoronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in Wuhan (China) by the end of 2019 (Zhu, Zhang et al. 2020), and it rapidly spread worldwide causing the coronavirus disease 2019 (COVID-19) global pandemic that was declared by the World Health Organization (WHO) on March 11th 2020 (Cucinotta and Vanelli 2020) and that has devastated the world for years.

56 COVID-19 is well known, including a huge variety of symptoms that normally appear four 57 to five days after the moment a person first become infected, ranging from mild symptoms to critical or possibly fatal illness (Gandhi, Lynch et al. 2020, Grant, Geoghegan et al. 2020). Thus, 58 59 the most common symptoms are fever, dry cough, sore throat, muscle and joint pain, fatigue, 60 headaches, anosmia, ageusia, nasal congestion and runny nose, diarrhea, eye irritation, and breathing difficulties in moderate to severe cases (Grant, Geoghegan et al. 2020, Wiersinga, 61 62 Rhodes et al. 2020). Although it seems clear that several factors, such as the health status of the patients prior to infection or the type of SARS-CoV-2 variant contracted, influence the severity of 63 the symptoms (Dao, Hoang et al. 2021, Inui, Fujikawa et al. 2022, Tyrkalska, Martinez-Lopez et 64 65 al. 2022, Yoon, Lee et al. 2023), the frequent appearance of totally different disease outcomes in apparently similar patients is still not understood at all. But it is even more difficult to understand 66 why, while the mentioned COVID-19 acute symptoms usually disappear within the next few 67 weeks after infection in most subjects, many acute COVID-19 convalescents experience persistent 68 69 symptoms after the acute infection that has been termed as long COVID, post-COVID-19 70 syndrome, post-acute COVID-19 syndrome (PACS), post-COVID-19 condition, chronic COVID syndrome (CCS), or post-acute sequelae of COVID-19 (PASC) (Greenhalgh, Knight et al. 2020, 71 Baig 2021). Even though the World Health Organization (WHO) proposed a clinical definition for 72 73 post-COVID-19 through a Delphi consensus in October 2021 stating that it generally occurs three 74 months after the onset of COVID-19, with symptoms lasting at least two months and not explained by an alternative (Soriano, Murthy et al. 2022), unfortunately, there is no consensus yet and, 75 therefore, the nomenclature, definition, epidemiology, pathogenesis, and mechanism of long 76 77 COVID are still unclear. Furthermore, as a consequence of this vagueness the prevalence of long 78 COVID is difficult to estimate, as it depends on the syndrome definition used, the time period taken into consideration in the study, and the study population, with multiple studies showing 79

It is made available under a CC-BY-NC-ND 4.0 International license .

percentages of SARS-CoV-2-infected subjects with long-term symptoms that range from less than 80 a 15% to over a 50% (Blomberg, Mohn et al. 2021, Taquet, Dercon et al. 2021). All these gaps in 81 knowledge of the disease, together with the difficulty in differentiating the symptoms of long 82 COVID from those of a normal, prolonged convalescence, or of other post-infection syndromes 83 triggered by infection and immune activation, such as post-viral fatigue (Behan and Behan 1988), 84 makes long COVID to be a diagnosis of exclusion (Leviner 2021). In any case, the main symptoms 85 that are usually attributed to long COVID include extreme fatigue, post-exertional malaise, 86 cognitive dysfunction, headaches, tinnitus, palpitations, chest pains, shortness of breath, sore 87 throat, long lasting cough, joint and muscle pain, feverishness, ageusia or dysgeusia, anosmia or 88 parosmia, diarrhoea, sleep difficulties, skin rash, and mental health problems such as depression 89 or changes in mood (Yelin, Wirtheim et al. 2020, Al-Aly, Xie et al. 2021, Davis, Assaf et al. 2021, 90 91 Lopez-Leon, Wegman-Ostrosky et al. 2021). But all these uncertainties and long-term symptoms of COVID-19, many of them with disabling consequences, are even more dramatic when the 92 patients who suffer from them are children, as they are in crucial stages of their development. 93 Although the severe forms of acute COVID-19 are less common in children than in adults (Chua, 94 Shah et al. 2021), and most of the published research on long-COVID primarily focuses on adult 95 populations, recent meta-analyses have revealed the presence of more than 40 long COVID 96 97 symptoms in children and adolescents, with a prevalence of one or more of these symptoms more than 4 weeks following a SARS-CoV-2 infection of 25.24% (Lopez-Leon, Wegman-Ostrosky et 98 99 al. 2022). According to other more worrying studies, the prevalence of pediatric long COVID could even reach 66% (Fainardi, Meoli et al. 2022). In children and adolescents, the most common 100 101 long-term symptoms and percentage of prevalence associated are mood symptoms (e.g., sadness, tension, anger, depression, and anxiety) (16.50%), fatigue (9.66%), sleep disorders (8.42%), 102 103 headache (7.84%), respiratory symptoms (7.62%), nasal congestion (7.53%), and cognitive 104 symptoms (e.g., less concentration, learning difficulties, confusion, and memory loss) (6.27%) (Gonzalez-Aumatell, Bovo et al. 2022, Lopez-Leon, Wegman-Ostrosky et al. 2022). 105

106 Considering all the above, it is clear that the elaboration of novel strategies and clinical 107 guidelines for the prevention, diagnosis, follow-up, and rehabilitation of long COVID, particularly 108 in children, is essential and for this purpose the study of possible biomarkers for this disease is of 109 great interest. These biomarkers should ideally: (1) be measured in biological samples that are easy 110 to collect and preferably by non-invasive methods, such as saliva; (2) be related with physiological

It is made available under a CC-BY-NC-ND 4.0 International license .

pathways that are altered in COVID-19; and (3) be measured with technology platforms and 111 optimized protocols for rapid analysis of the biomarkers. Saliva is an extracellular biofluid with 112 multiple biomedical applications, with the advantage that it is easy, safe, cheap, and quick to 113 collect, without any pain or stress (Yoshizawa, Schafer et al. 2013). Saliva has often been 114 considered as a 'mirror of the body', since it is an outstanding surrogate medium that cannot reflect 115 116 only the physiological and physiopathological state of the oral cavity, but also of the whole organism (Lee and Wong 2009). Although human saliva comprises 99.5% water, it presents a 117 complex composition including many important substances, being enzymes, proteins, 118 immunoglobulins, DNA and RNA of host origin, bacteria and bacterial products, host cells, steroid 119 hormones, ions, and volatile compounds, the main salivary diagnostic analytes (Zhang, Xiao et al. 120 2009). 121

122 Among the physiological pathways that can be analyzed in saliva, there are biomarkers of redox status, immune response, and stress. Given that oxidative stress has been associated with 123 124 multiple human diseases (Vona, Pallotta et al. 2021), the measurement of biomarkers that reflect the redox status of the individuals can be useful when studying the pathogenesis of a disease. Some 125 126 of the most used salivary biomarkers to measure this are the total oxidant status (TOS), the advanced oxidation protein products (AOPP), the derivatives of reactive oxygen metabolites (d-127 128 ROMs), the levels of Trolox equivalent antioxidant capacity in the hydrophilic fraction (TEACH), the cupric reducing antioxidant capacity (CUPRAC), and the ferric reducing ability of plasma 129 (FRAP) (Tvarijonaviciute, Aznar-Cayuela et al. 2018, Rubio and Cerón 2021). Regarding the 130 evaluation of the immune response, adenosine deaminase (ADA) and its isoenzymes, ADA1 and 131 132 ADA2, ferritin, and total proteins are particularly interesting. The level of ADA enzymatic activity in serum reflects the cell-mediated immunity (Baganha, Pêgo et al. 1990) because, in lymphoid 133 tissues, ADA participates in mononuclear cell maturation from monocyte to macrophage, as well 134 135 as in the differentiation of B and T lymphocytes (Sullivan, Osborne et al. 1977, MacDermott, Tritsch et al. 1980). Thus, the serum level of ADA is considered as a biomarker of situations with 136 high levels of circulating T lymphocytes (Calis, Ates et al. 2005) and chronic inflammation 137 (Mishra, Gupta et al. 1994), with significant increases in infection (Vijayamahantesh, Amit et al. 138 2016), inflammation (Santosh, Renukananda et al. 2016), malignancies (Ebrahimi-Rad, Khatami 139 et al. 2018), and immunomediated disorders (Sari, Taysi et al. 2003). Importantly, it has already 140 141 been demonstrated that total ADA (tADA) and its isoenzymes ADA1 and ADA2 can be measured

It is made available under a CC-BY-NC-ND 4.0 International license .

accurately in saliva samples, even after the chemical inactivation of SARS-CoV-2, and that their 142 levels are significantly increased in saliva of COVID-19 patients compared to healthy controls 143 144 (Franco-Martínez, Tecles et al. 2021). Also important for monitoring the immune response is serum ferritin which, besides its role as an iron storage protein, has also been described as an 145 essential molecule in the immune system with immunosuppressive and pro-inflammatory effects 146 (Sharif, Vieira Borba et al. 2018). Hence, a high level of ferritin in serum is considered as a marker 147 of inflammatory, autoimmune, malignant, or infectious status, including COVID-19 (Zandman-148 Goddard and Shoenfeld 2007, Vargas-Vargas and Cortés-Rojo 2020). Interestingly, ferritin levels 149 are increased in saliva of COVID-19 patients and, even more important, those levels directly 150 151 correlate with the severity of the disease (Franco-Martínez, Cerón et al. 2021). Levels of total proteins in saliva are known to be significantly increased in multiple diseases (Shaila, Pai et al. 152 153 2013, Masters, Noyce et al. 2015), which can make it a biomarker of interest. Regarding biomarkers of stress, the measurement of salivary alpha-amylase (sAA) levels can also be very 154 informative, since it is secreted by the parotid gland in response to sympathetic-adrenal-medullary 155 system and increases in psychological and intense physical stress situations (Nater and Rohleder 156 157 2009). Indeed, sAA levels are increased in COVID-19 patients, positively correlating with their mental stress scores (Deneva, Ianakiev et al. 2022). 158

159 The objective of this work was to study the changes in the levels of a panel of different 160 biomarkers measured in saliva, able to provide information about redox status, immune response, 161 and stress of children with long COVID, and the correlations between these biomarkers as well as between them and multiple demographic/clinical parameters. Based on this data, we have 162 163 developed predictive models to determine whether the measurement of these salivary biomarkers would be enough to reliably discriminate between children with long COVID and healthy controls, 164 and between children with long COVID who present a severe form of the disease and those others 165 who only have mild symptoms. This information could be of interest for a better understanding of 166 pediatric long COVID, and to develop novel strategies that facilitate an early treatment that reduces 167 the sequelae of the disease. 168

169

### 170 **RESULTS**

171 Sample overview

It is made available under a CC-BY-NC-ND 4.0 International license .

A total of 105 saliva samples, 49 from children with long COVID and 56 from controls of 172 the same age range (with average ages of 13.3 and 11.6 years, respectively), were collected and 173 174 included in this study for analysis. Demographic and clinical information of patients with long COVID was gathered as well, aiming to check any potential associations between these data and 175 the different salivary biomarker levels measured in this work. Thus, data about previous relevant 176 diseases obtained from the patient personal health records, as well as clinical condition measured 177 after the diagnosis of long COVID, were collected to monitor the development of the disease 178 (Table 1). Consistent with previous studies suggesting that pediatric long COVID may have an 179 important impact on health (Lopez-Leon, Wegman-Ostrosky et al. 2022), our analysis of clinical 180 data from children with the disease enrolled in this study revealed the great threat that long COVID 181 poses to their health and normal development. Indeed, as many as 28.6% of them presented a 182 183 severe form of the disease, including highly disabling symptoms such as extreme fatigue (44.9%), CNS symptoms (79.6%), brain fog (59.2%), respiratory symptoms (59.2%), cardiovascular 184 symptoms (65.3%), and insomnia (46.9%) (Table 1). 185

186

### 187 Salivary biomarker levels are altered in children with long COVID

The levels of 13 biomarkers were measured in saliva of children with long COVID and controls. These biomarkers were selected based on the potentially high relevance of the information that they were presumably able to provide us about the redox status (TOS, AOPP, D-ROMS, TEACH, CUPRAC, and FRAP), the immune response (ADA1, ADA2, tADA, ferritin, and Ig-RBD), the acute stress levels (sAA), and the general homeostatic status (total proteins) of children included in this study.

194 As a first and simple approach to check whether salivary biomarker levels were altered in 195 children with long COVID compared to controls, these levels were analyzed jointly. For this, we performed Principal Component Analysis (PCA) to visualize the biomarker level patterns of all 196 samples in a low-dimension space based on the salivary level matrix of the 13 biomarkers across 197 198 the 105 samples. Thus, the top two principal components explained 27.1% and 23.7% of the variance of the original data, respectively (Figure 1A). As shown in Figure 1A, the samples 199 apparently did not form two clearly different clusters as they appeared mostly intermixed, both 200 201 centroids were not far apart from each other, and the confidence ellipses chiefly overlapped.

It is made available under a CC-BY-NC-ND 4.0 International license .

However, a closer look to these PCA results revealed that while most samples located in the upper left quadrant corresponded to children with long COVID and just a few of them to controls (18 vs. 6, respectively), exactly the opposite situation was observed in the lower right quadrant (6 vs. 24, respectively) (Figure 1A). Therefore, although samples from long COVID patients and those from controls did not form two clearly separate clusters, PCA results suggested that there could be significant differences in salivary biomarker levels between both groups that deserved further research.

Our moderately promising preliminary foray into the study of the salivary biomarker levels 209 of children with long COVID and controls by PCA (Figure 1A), led us to go further and analyze 210 211 in detail the differences between both groups of children for each of the 13 salivary biomarkers included in this study individually. Interestingly, we found that while the levels of the oxidant 212 213 biomarkers TOS and D-ROMS were increased in children with long COVID compared to controls, exactly the opposite result was observed for the antioxidant biomarkers TEACH, CUPRAC, and 214 215 FRAP, whose levels were significantly reduced in children with long COVID (Figure 1B). Curiously, the only salivary biomarker of this group that did not follow the same pattern was 216 217 AOPP, as its level was increased in children with long COVID albeit it is a measurement of the oxidative protein products (Figure 1B). Furthermore, it was surprising to observe that the levels of 218 219 only two of the five biomarkers measured to evaluate the immune response, ADA2 and tADA, 220 were significantly altered in saliva of children with long COVID compared to controls (Figure 221 **IC**). Finally, the sAA and total protein levels, that usually increased in disease (Nater and Rohleder 2009, Shaila, Pai et al. 2013, Masters, Noyce et al. 2015, Deneva, Ianakiev et al. 2022), were 222 223 significantly reduced in children with long COVID compared to controls (Figures 1D and 1E).

224

### Correlation patterns between the different salivary biomarkers are altered in children with long COVID

After finding clear differences when comparing the salivary biomarker levels of children with long COVID and controls in many cases (Figures 1B-1E), and aiming to obtain more information which could help us understand better the biological relevance of such differences, we checked whether there were significant correlations between the levels of the different salivary biomarkers included in this study. For this purpose, we used the Pearson correlation coefficient to

It is made available under a CC-BY-NC-ND 4.0 International license .

measure the lineal correlation for all the possible biomarker pairs, and the magnitudes (colors) and 232 statistical significances (asterisks) of all these correlation analyses were displayed in a diagram to 233 234 facilitate the joint interpretation of the results (Figure 2A). As expected, the highest correlations were those found between salivary biomarkers that are functionally related, such as the high 235 positive correlations observed for the pairs FRAP-TEACH, CUPRAC-TEACH, FRAP-CUPRAC, 236 ADA1-tADA, and ADA2-tADA (Figure 2A). Curiously, while some biomarkers presented 237 significant correlations with many others, as in the cases of TEACH and the total amount of 238 proteins in saliva, whose levels significantly correlated with 7 of the other 12 biomarkers in both 239 cases, others significantly correlated with only a couple of the other biomarkers (TOS) or even 240 with none of them (IgRBD) (Figure 2A). 241

The existence of significant correlations between salivary biomarkers in several cases 242 243 (Figure 2A), together with the fact that one of our main goals is to be able to discriminate between children with long COVID and controls reliably, led us to wonder if both groups of children could 244 245 present different correlation patterns. Thus, we decided to repeat the same analysis of correlations but this time for controls and children with long COVID separately, and results were represented 246 247 in two diagrams to be able to visually compare them more easily (Figure 2B). These analyses revealed that the total number of salivary biomarker pairs with a significant correlation was almost 248 249 equal in both groups of children (24 vs. 23, respectively) (Figure 2B). However, a closer look at the results showed that several correlations observed in control children, particularly those between 250 251 the salivary biomarkers measured to evaluate the oxidative status (i.e. TEACH-D-ROMS, 252 CUPRAC-AOPP, or FRAP-AOPP), were no longer statistically significant in children with long 253 COVID (Figure 2B). In the opposite direction, the case of sAA drew special attention as it went from not significantly correlating with any other salivary biomarker in controls to doing so with 254 AOPP, D-ROMS, TEACH, and CUPRAC in children with long COVID (Figure 2B). 255

In summary, these results demonstrate that not only the levels of most of the salivary biomarkers included in this study are altered in children with long COVID compared to controls (Figures 1B-1E), but also that the correlation patterns between such biomarkers are significantly different when comparing both groups of children (Figure 2B). Therefore, both types of differences could potentially be useful to discriminate between children with long COVID and those who do not suffer from the disease.

It is made available under a CC-BY-NC-ND 4.0 International license .

262

### Salivary biomarker levels are useful to reliably discriminate between children with long COVID and controls, and also between children with mild and severe long COVID symptoms

Given that levels of 9 of the 13 salivary biomarkers measured in this study were altered in 266 children with long COVID (Figures 1B-1E), and that the correlation patterns between the different 267 268 biomarkers were also significantly distinct in these children in many cases (Figure 2B), we decided 269 to study in detail how useful these salivary biomarkers could really be in discriminating between children with long COVID and controls. Hence, a multivariate logistic regression analysis was 270 271 performed to determine which of our 13 salivary biomarkers were the most explanatory variables 272 regarding the differences between both groups of children. Importantly, this analysis showed that TOS, ADA2, total proteins, and AOPP, in combination, were the variables that best discriminated 273 between children with long COVID and controls. Indeed, consistent with the idea that these four 274 salivary biomarkers could be useful to discriminate between both groups of children and contrary 275 to the observed in the previous PCA that included all the biomarkers (Figure 1A), a new PCA 276 analysis performed with a matrix containing the levels of only these 4 salivary biomarkers across 277 our 105 samples resulted in two clearly different distribution patterns when comparing children 278 with long COVID and controls (Figure 3A). In this case, the top two principal components 279 explained 36% and 25.8% of the variance of the original data, respectively, and the confidence 280 ellipses were distinct (Figure 3A). To further confirm the utility of TOS, ADA2, total proteins, and 281 AOPP, combined, to discriminate between children with long COVID and controls, we elaborated 282 a predictive model with these four salivary biomarkers and tested it. Thus, 85% of all our samples 283 were used to elaborate and train the predictive model, while the remaining 15% of samples were 284 285 utilized to test it, finding that the model presented very high accuracy, 86.67% (95% CI: 0.5954, 0.9834), with a sensitivity of 0.875 and a specificity of 0.857. Furthermore, this predictive model 286 was also evaluated by performing a receiver operating characteristic (ROC) curve, which is a 287 graphical plot that illustrates the diagnostic ability of a binary classifier system as its discrimination 288 threshold is varied (Fawcett 2006), resulting in an outstanding area under the curve of 0.906 and, 289 290 therefore, confirming the strength and potential utility of our predictive model (Figure 3B).

It is made available under a CC-BY-NC-ND 4.0 International license .

The exceptional finding that 4 of the salivary biomarkers measured in this study could be 291 used to reliably discriminate between children with long COVID and controls, prompted us to 292 293 check, in a similar way, whether we were able to focus on the group of children with long COVID 294 and use the biomarkers to discriminate between children who present a severe form of the disease and those others who only have mild symptoms. In this case, the multivariate logistic regression 295 analysis using the forward and backward stepwise regression method (Efroymson and MA 1960) 296 revealed that total proteins and ADA1, in combination, were the variables that best discriminated 297 between children with mild and severe long COVID symptoms. Accordingly, whereas a PCA 298 analysis performed with a matrix containing the levels of the 13 salivary biomarkers measured in 299 this study across the 49 samples from children with long COVID resulted in two mostly 300 overlapping confidence ellipses (Figure 3C), another PCA analysis performed with a matrix 301 containing only the levels of total proteins and ADA1 across the same 49 samples showed two 302 more different confidence ellipses as expected (Figure 3D). To further confirm the utility of total 303 proteins and ADA1, combined, to discriminate between children with mild and severe long 304 COVID symptoms, we elaborated a predictive model with these two salivary biomarkers and 305 306 tested it as previously explained. This time, the model presented an accuracy of 71.43% (95% CI: 0.29, 0.96), with a sensitivity of 0.50 and a specificity of 0.80. Finally, the ROC curve for this 307 308 predictive model showed an area under the curve of 0.796, suggesting that our model has good discriminatory ability (Figure 3E). 309

All these data together strongly suggest that the combination of the salivary biomarkers TOS, ADA2, total proteins, and AOPP could be useful to reliably discriminate between children with long COVID and controls, while the combination of total proteins and ADA1 could provide us with a tool to discriminate between children with mild and severe long COVID symptoms. Crucially, both findings could have a huge potential usefulness at the diagnosis and prognosis levels.

316

### Salivary biomarker levels correlate with different demographic and clinical parameters in children with long COVID

After finding that levels of the salivary biomarkers could be useful to discriminate between children with long COVID and controls, and between children with mild and severe long COVID

It is made available under a CC-BY-NC-ND 4.0 International license .

symptoms, we aimed to investigate the potential correlations among the different salivary 321 biomarker levels and the demographic and clinical parameters available from children with long 322 323 COVID included in this study. Results of the ability of each biomarker to predict the different 324 demographic and clinical parameters were represented in a diagram to be able to visualize them more easily (Figure 4). Interestingly, while several parameters such as the fatigue test results 325 correlated with the levels of multiple salivary biomarkers (8), others such as the gender only 326 correlated with the levels of one salivary biomarker (TOS) (Figure 4). From the point of view of 327 biomarkers, the case of total proteins drew attention, since its level correlated with 8 demographic 328 and clinical parameters, 5 of them in a statistically significant manner (Figure 4). 329

330

### 331 **DISCUSSION**

In this study, we have tried to shed light on the still lacunar knowledge on pediatric long 332 333 COVID by taking advantage of our invaluable saliva samples from children diagnosed with the disease, together with an equally precious set of demographic and clinical data associated with 334 such samples. The great relevance of pediatric long COVID and, therefore, the need to study it, 335 comes not only from its high incidence as it appears in more than 25% of children infected by 336 SARS-CoV-2 (Lopez-Leon, Wegman-Ostrosky et al. 2022), but also from the fact that more than 337 28% of children with long COVID present serious symptoms as consequence of this disease, 338 339 according to our data (Table 1). Even though the most worrying consequence of long COVID in children is the prevalence of symptoms affecting so important systems as the central nervous 340 (79.6%), the respiratory (59.2%), and the cardiovascular (65.3%) systems, among others, it is also 341 342 alarming that a high percentage of these children see their school attendance (28.6%), school performance (44.9%), and participation in extracurricular activities (49.0%) altered (Table 1). 343 Therefore, all this together could cause serious and difficult to recover developmental alterations 344 345 in children.

The measurement of the levels of several salivary biomarkers to check whether children with long COVID were suffering from oxidative stress, revealed significant changes but reflect an apparent state of balance. Thus, while the levels of the antioxidant biomarkers TEACH, CUPRAC, and FRAP decreased in saliva of children with long COVID compared to controls, the opposite trend was observed for the oxidant biomarkers TOS and d-ROMs. The only exception was the

It is made available under a CC-BY-NC-ND 4.0 International license .

oxidant biomarker AOPP whose levels decreased in children with long COVID, probably because 351 352 the total protein levels also decreased in saliva of these children compared to controls. Salivary 353 tADA, ADA1, and ADA2 levels provided relevant information regarding the immune response 354 that was underway in children with long COVID. Given the prominent role of ADA in mononuclear cell maturation from monocyte to macrophage and in the differentiation of B and T 355 356 lymphocytes (Sullivan, Osborne et al. 1977, MacDermott, Tritsch et al. 1980, Baganha, Pêgo et 357 al. 1990), the increased levels of tADA and ADA2 in saliva of children with long COVID suggested that cell-mediated immunity could be more important than humoral immunity in the 358 response of children against long COVID. Intriguingly, ADA1 levels did not change in saliva of 359 children with long COVID. However, this is not so strange since it has recently been reported that 360 tADA and ADA2 levels change in serum of individuals 8 weeks after diagnosis of acute COVID-361 362 19 by PCR, whereas ADA1 levels do not change (Jedrzejewska, Kawecka et al. 2023). Furthermore, it is also not surprising that in this mentioned study the levels of tADA and ADA2 363 364 in serum decreased (Jedrzejewska, Kawecka et al. 2023) while in our work they increased in saliva, as it has been previously shown that tADA and its isoforms can respond to inflammation 365 366 differently in serum or saliva (Contreras-Aguilar, Tvarijonaviciute et al. 2020). Although it has previously been reported that ferritin levels are dramatically increased in saliva of patients with 367 368 acute COVID-19 (Franco-Martínez, Cerón et al. 2021), we did not find salivary ferritin levels to be elevated in children with long COVID compared to controls. Therefore, the potentiality of 369 370 salivary ferritin levels to differentiate between the acute and the chronic phases of COVID-19 in children deserve further research. Surprisingly, we found that sAA and total protein levels were 371 372 reduced in saliva of children with long COVID compared to controls, while both biomarkers use 373 to be increased in disease (Nater and Rohleder 2009, Shaila, Pai et al. 2013, Masters, Novce et al. 374 2015, Deneva, Ianakiev et al. 2022). Nevertheless, our sAA results are consistent with previous 375 studies showing that sAA levels decrease in both, rats and children, with chronic stress (Wolf, Nicholls et al. 2008, Matsuura, Takimura et al. 2012). The reduced levels of total proteins observed 376 in saliva of children with long COVID are more difficult to explain, and further research on this 377 378 would require delving deeper into the eating habits of these children, since it could simply be due 379 to a reduction in their intake.

Given that one of the main objectives of this work was the development of some simple,fast and cheap methods capable of discriminating between children with long COVID and controls,

It is made available under a CC-BY-NC-ND 4.0 International license .

using samples that can also be obtained quickly, cheaply and minimally invasive, we did not limit 382 our study to the measurement of salivary biomarkers individually, which could also present a high 383 384 intrinsic variability between different subjects. Therefore, in addition to study changes in the levels of the different biomarkers separately, we also analyzed the correlations between all biomarker 385 pairs to identify any correlation patterns that could exist and be considered as a characteristic 386 signature of children with long COVID. If this signature exists, it could allow us to differentiate 387 these children from controls through a simple correlation analysis, and probably without the need 388 to measure more than a few biomarkers. The analysis of correlations including all samples, both 389 from children with long covid and controls, helped us to verify that, as expected, the highest 390 correlations were those between functionally related biomarkers (CUPRAC-TEACH, FRAP-391 TEACH, FRAP-CUPRAC, ADA1-tADA, ADA2-tADA, among others). Although expected, this 392 393 result was still important because it served as a control to show us that our correlation analyses were reliable. Interestingly, the comparison between the salivary biomarker correlation patterns of 394 children with long COVID and controls revealed important differences, highlighting the fact that 395 sAA levels went from not correlating with any other biomarkers in control children to significantly 396 397 correlating with the levels of other 5 biomarkers (AOPP, DROMS, TEACH, CUPRAC, and total proteins) in children with long COVID. Interestingly, when we incorporated to our correlation 398 399 analyses a group of demographic/clinical variables from the children with long COVID included in this study, we found significant correlations between the levels of the salivary biomarker and 400 401 these variables in 19 cases. Particularly remarkable were the cases of ferritin, TEACH, and total proteins because they were the biomarkers whose levels correlated with more of the 402 403 demographic/clinical variables (with 3, 4, and 5, respectively). Importantly, we found a significant correlation between the salivary ferritin levels and the fatigue test, supporting our previously 404 405 mentioned idea that iron levels might be altered in children with long COVID. Moreover, these analyses also revealed significant correlations between the sAA levels and two of the 406 demographic/clinical variables: the school performance and the fatigue test. This is consistent with 407 several previous studies reporting a clear association between reduced sAA levels and performance 408 409 deficits during sleep loss (note that almost 47% of children with long COVID suffer from 410 insomnia) (Pajcin, Banks et al. 2017), and between sAA levels and mental disorders in children (Jezova, Trebaticka et al. 2020). 411

It is made available under a CC-BY-NC-ND 4.0 International license .

The facts that (1) levels of most of the salivary biomarkers measured in this study (9 out of 412 13) were altered in children with long COVID, and (2) children with long COVID presented a 413 414 characteristic pattern of correlations between the distinct biomarkers significantly different from 415 that of control children, clearly suggested that these biomarkers could be useful for discriminating between both groups of children. These promising results prompted us to further refine our 416 analyses by using a multivariate logistic regression analysis, finding that, among all the possible 417 combinations of the 13 biomarkers included in this work, TOS, ADA2, total proteins, and AOPP, 418 in combination, were the variables that best discriminated between children with long COVID and 419 controls. But the great relevance of this discovery was not in which those 4 variables were, but in 420 the outstanding soundness of the predictive model that included them, whose accuracy was 86.67% 421 and with an area under the ROC curve of 0.906. Consistent with these results, our PCA analyses 422 confirmed that the group composed only of the 4 salivary biomarkers TOS, ADA2, total proteins, 423 and AOPP was able to discriminate between children with long COVID and controls better than 424 using the 13 biomarkers included in this study together. This could have important implications 425 from a practical point of view, since it meant that it would be enough to measure the levels of only 426 427 those 4 biomarkers to be able to discriminate between both groups of children reliably. It would be extremely useful if the levels of the salivary biomarkers also allowed us to discriminate between 428 429 children with long COVID who will present a mild form of the disease and those who will suffer severe symptoms. The multivariate logistic regression analysis performed to check this possibility 430 431 showed that the group composed only of the 2 biomarkers total proteins and ADA1 was the one which best discriminated between children with mild and severe long COVID symptoms. 432 433 Although these results were not as extraordinarily good as in the previous case from a statistical point of view, the predictive model including only total proteins and ADA1 had a still notable 434 435 accuracy of 71.43% and an area under the ROC curve of 0.796, suggesting that they could be 436 useful to discriminate between both groups of children. As in the previous case, the comparison of the PCA analyses including the 13 salivary biomarkers measured in this work or only total proteins 437 and ADA1, confirmed that using only these two biomarkers we could better discriminate between 438 children with mild and severe long COVID symptoms. 439

Despite the efforts of the WHO to establish a consensus that serves to clinically define long
COVID (Soriano, Murthy et al. 2022), there is still no general agreement, leading to a great
disparity in the criteria used to identify symptoms and diagnose the disease. As a result of these

It is made available under a CC-BY-NC-ND 4.0 International license .

differences, not only the nomenclature, definition, epidemiology, and pathogenesis of long COVID 443 are still unclear, but also its prevalence that varies from less than a 15% to over a 66% depending 444 445 on the diagnostic criteria used (Blomberg, Mohn et al. 2021, Taquet, Dercon et al. 2021). This conundrum hinders the research into the disease pathogenesis, its approach from a clinical point 446 of view, and the work of raising awareness among the population and institutions about its high 447 relevance and the need to study it. Importantly, this study demonstrates that the levels of only a 448 few biomarkers (TOS, ADA2, total proteins, and AOPP) that can be measured in saliva in a simple, 449 fast, cheap and minimally invasive way, can be used to differentiate between children suffering 450 from long COVID and healthy controls, or in other words, as a tool to help diagnose the disease 451 in children following objective and standardized criteria that could be easily adopted in any 452 hospital. In the same way, the levels of only a couple of salivary biomarkers (total proteins and 453 454 ADA1) could help us to reliably and objectively classify which children with long COVID suffer from a severe form of the disease and which do not. Although this diagnostic use of the salivary 455 biomarkers undoubtedly is very important and helpful to shed light on the field of pediatric long 456 457 COVID, the ideal situation would be to be able to use them also as prognosis biomarkers to foresee 458 which of the children infected by SARS-CoV-2 will be more likely to develop long COVID and, in addition, which of them will be more likely to develop serious symptoms of the disease. Thus, 459 460 by diagnosing children at early stages of long COVID and predicting how their disease will progress, they could benefit from early monitoring and initiation of treatments and therapies 461 462 relieving the severity of symptoms, thus, limiting possible alterations in their development. The results we report here are promising if we think about the possibility of using salivary biomarkers 463 464 for prognosis of pediatric long COVID, albeit further research is needed to explore this possibility by measuring the levels of the distinct biomarkers in saliva of children at different times, ideally 465 466 from the time of SARS-CoV-2 infection. Hence, the moment when levels of the different salivary biomarkers begin to change significantly, and the study of their kinetics is what would indicate 467 which of the biomarkers could have a prognostic use. 468

This work has several strengths, many of them uncommon in this area of study: (1) it addresses a relevant but still understudied biomedical question such as pediatric long COVID; (2) collection of data was standardized in advance; (3) saliva levels of a wide variety of biomarkers were measured, providing us with information about different host responses; (4) sample sizes are very high; and (5) we have a highly valuable set of demographic/clinical data from children with

It is made available under a CC-BY-NC-ND 4.0 International license .

long COVID. However, our study also presents several limitations that should be addressed in the 474 future research: (1) we did not have the necessary saliva samples to measure the biomarker levels 475 476 at different time points after infection of children with SARS-CoV-2, which would be useful to 477 determine whether such biomarkers are useful for prognostic purposes and (2) we did not have a third group of children with another disease to compare and confirm that our findings are specific 478 for long COVID. However, regarding this last issue, all our analyses were performed using the 479 specific levels of different combinations of several biomarkers, making improbable that the same 480 changes in the same groups of biomarkers appear in saliva of children in response to other diseases. 481

In summary, our study demonstrates that salivary biomarkers can be important tools to help diagnose pediatric long COVID and classify its severity in an objective and standardized manner and paves the way for future studies that explore the possibility that such biomarkers can also be used for prognostic purposes.

486

### 487 METHODS

### 488 Saliva samples and patient information collection

Saliva samples were collected from 49 children between 9 and 18 years of age, who had 489 490 been diagnosed with long COVID by pediatricians at the Unidad de Covid Persistente Pediátrico 491 of the Hospital Universitario Germans Trias i Pujol (Badalona, Spain). As a control, saliva samples were also collected from 56 healthy children within the same age range. In all cases, saliva samples 492 were obtained under supervision using a salivette® device (Sarstedt, Germany). Participants were 493 instructed to chew the cotton swab of the salivette® device for 1 minute and then the swab was 494 transferred into the salivette® tube and centrifuged at 4500 rpm for 10 min. Participants were 495 requested to refrain from eating, drinking, and performing basic oral hygiene for 1 h before sample 496 497 collection. No samples showed blood contamination as determined by visual inspection. Inactivation of potential infectious viruses was performed by incubation with Np-40 to a final 498 concentration of 0.5% for 30 minutes and were stored at -80 °C until further analysis. Regarding 499 the inclusion criteria, participants were included in this study if they: (1) presented three or more 500 compatible symptoms lasting longer than twelve weeks after SARS-CoV-2 infection, regardless 501 of previous hospital admission, (2) had a positive diagnosis of SARS-CoV-2 infection or clinical 502

It is made available under a CC-BY-NC-ND 4.0 International license .

suspicion (i.e., COVID-19 symptoms in participants with a close relative who had confirmation of 503 SARS-CoV-2 infection in a situation of community transmission at the beginning of the pandemic, 504 505 March 2020, when it was not possible to access to test), and (3) had persisting symptoms that were 506 not present before COVID-19 infection. Participants were excluded if they were unable to sign the informed consent, attend the follow-up visits, or presented an alternative diagnosis. Patients who 507 508 could continue with their usual activities although they presented fatigue were considered to have mild severity, those who were able to continue attending school but had to stop playing sports and 509 extracurricular activities were considered to have moderate severity, and those who could not 510 attend school normally were considered to have severe long COVID. 511

Besides the saliva samples, we collected abundant demographic and clinical information on the children with long COVID from two different sources, i.e., their clinical examinations and their patient clinical histories, aiming to facilitate the identification of any potential correlations that could exist between the biological parameters measured in the saliva samples and these demographic/clinical variables (Table 1).

517

### 518 Measurement of salivary biomarker levels

519 Total oxidant status (TOS) was measured following the method of Erel and colleagues (Erel 2005) adapted to saliva samples. The assay is based on the oxidation of ferrous to ferric ion 520 521 in the presence of various oxidant species in acidic medium. Reactive oxygen metabolites derived compounds (d-ROMs) were measured by the method described in Cesarone and colleagues 522 523 (Cesarone, Belcaro et al. 1999), which is based on the capacity of transition metals to catalyse in 524 the presence of peroxides with formation of free radicals. The trolox equivalent antioxidant 525 capacity (TEACH) was quantified by a method based on the capacity of the the antioxidants present in the sample to reduce the ABTS, as previously reported (Barranco, Rubio et al. 2019). 526 Cupric reducing antioxidant capacity (CUPRAC) was measured as previously described 527 (Tvarijonaviciute, Aznar-Cayuela et al. 2017), and is based on the reduction of cupric to cuprous 528 ion by the antioxidants present in the sample. Ferric reducing ability of plasma (FRAP) was 529 530 measured in saliva following the method described by Benzie and Strain (Benzie and Strain 1996), which measures the capacity of the sample to reduce ferric to ferrous ion as previously described 531 and validated (Tvarijonaviciute, Aznar-Cayuela et al. 2017). Salivary protein oxidation status was 532

It is made available under a CC-BY-NC-ND 4.0 International license .

evaluated by measuring advanced oxidation protein product (AOPP) concentrations, as previously 533 described by Witko-Sarsat and colleagues (Witko-Sarsat, Friedlander et al. 1996). Salivary levels 534 535 of adenosine deaminase (tADA) and its isoenzymes, ADA1 and ADA2, were measured as previously described and validated (Franco-Martínez, Tecles et al. 2021). In brief, tADA was 536 measured using a commercially available spectrophotometric assay (Adenosine Deaminase assay 537 kit, Diazyme Laboratories, Poway, California, USA) without any treatment. Then, erythro-9-(2-538 hydroxy-3-nonyl) adenine (EHNA) was added to Reagent 1 and values of ADA2 and ADA1 were 539 determined. Ferritin was measured by a commercial immunoturbidimetric assay that uses 540 polyclonal anti-human ferritin antibodies (Tina-quant ferritin, Roche Diagnostics, Indianapolis, 541 United States) in an automated analyzer (Olympus AU400 automated biochemical analyzer, 542 Olympus Diagnostica GmbH, Ennis, Ireland). The assay was adapted from serum to saliva as 543 544 previously reported (Franco-Martínez, Tvarijonaviciute et al. 2019). Salivary alpha-amylase (sAA) activity was measured using a colorimetric commercial kit (Alpha-Amylase, Beckman 545 546 Coulter Inc., Fullerton, CA, USA) following the International Medicine (IFCC) method (1999, Rohleder and Nater 2009), as previously reported and validated (Tecles, Fuentes-Rubio et al. 547 548 2014). Total protein levels in saliva were measured using a colorimetric assay (protein in urine and CSF, Spinreact, Spain) following the manufacturer's instructions. Salivary anti SARS-CoV-2 549 550 RBD IgG (IgG-RBD) levels were measured by a method developed and validated in the authors laboratory (Martínez-Subiela, Franco-Martínez et al. 2022). All measurements were performed in 551 552 an automated analyser (Olympus AU400 automated biochemical analyzer, Olympus Diagnostica GmbH, Ennis, Ireland) except anti SARS-CoV-2 RBD IgG that were measured in EnSpireAlpha 553 plate Reader (PerkinElmer (MA, USA). 554

555

### 556 **Bioinformatics and statistical analysis**

All the bioinformatic analyses included in this study were performed with R (v.4.3.1) (https://www.R-project.org/). Principal component analyses (PCA) were conducted using the R package for multivariate analysis FactoMineR (S Lê , J Josse et al. 2008) to check, based on the levels of the different salivary biomarkers tested in each case, whether there was a significant separation between children with long COVID and control children, or between children with long COVID displaying a severe form of the disease and those others with mild symptoms. Levels of

It is made available under a CC-BY-NC-ND 4.0 International license .

each salivary biomarker in children with long COVID and controls were represented in violin plots 563 using GraphPad Prism (version 8.0.2 for Windows, GraphPad Software, Boston, Massachusetts 564 565 USA, www.graphpad.com), and the same software was used to analyze the differences between both groups by Student's t-test. The R package corrplot (https://github.com/taiyun/corrplot) was 566 used to study the correlations between the levels of the different salivary biomarkers in (1) all the 567 568 individuals, (2) healthy controls, and (3) individuals with long COVID, by calculating the Pearson correlation coefficient for all the possible biomarker pairs. Moreover, the same methodology was 569 used to study the correlations between the levels of the salivary biomarkers and the 570 demographic/clinical variables in children with long COVID. A multivariate logistic regression 571 analysis using the forward and backward stepwise regression method (Efroymson and MA 1960) 572 was performed to identify which variables best discriminated between children with long COVID 573 574 and controls in one case, or between children with long COVID displaying a severe form of the disease and those others with mild symptoms in another case. This bi-directional stepwise 575 576 procedure is a combination of forward and backward selection and elimination that tests the variables evaluated and all their possible combinations, using at every step the t statistics for the 577 578 coefficients of the variables being considered (Efroymson and MA 1960). Once the variables that best discriminated between groups of children were identified (TOS, ADA2, total proteins, and 579 580 AOPP to discriminate between children with long COVID and controls, and total proteins and ADA1 to discriminate between children with long COVID displaying a severe form of the disease 581 582 and those others with mild symptoms), only those selected biomarkers were used to perform regression predictive models by using data from 85% of individuals to train the models, and from 583 584 the remaining 15% of subjects to test them. These predictive models were also evaluated by performing ROC curves using the R package pROC (Robin, Turck et al. 2011). The R package 585 586 ggplot2 version 3.4.3 was used to generate all the diagrams showing the results of the correlation 587 analyses (H 2016).

588

### 589 Acknowledgements

This work was supported by the grant 00006/COVI/20 to VM and MLC funded by Fundación
Séneca-Murcia, the Saavedra Fajardo contract 21118/SF/19 to SC funded by Fundación SénecaMurcia, the Juan de la Cierva-Incorporación contract to SDT funded by Ministerio de Ciencia y

It is made available under a CC-BY-NC-ND 4.0 International license .

593 Tecnología/AEI/FEDER. The funders had no role in the study design, data collection and analysis,

decision to publish, or preparation of the manuscript.

595

### 596 Authors' contributions

The authors offer the following declarations about their contributions: Conceived and designed the experiments: SC, MLC and VM. Performed the experiments: SC, SDT, FPS and SMS. Analyzed the data: SC, SDT, FPS, SMS, MMH, JJC, MLC, VM. Provided patients' samples and clinical data: MMH, AGA, CCA, EDM. Writing-original draft: SC. Writing-review & editing: MLC, VM, MMH, AGA, SMS, JJC. All authors have read and agreed to the published version of the manuscript.

603

### 604 Funding

This work was supported by the grant 00006/COVI/20 to VM and MLC funded by Fundación Séneca-Murcia, the Saavedra Fajardo contract 21118/SF/19 to SC funded by Fundación Séneca-Murcia, the Juan de la Cierva-Incorporación contract to SDT funded by Ministerio de Ciencia y Tecnología/AEI/FEDER. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

610

### 611 Ethics approval and consent to participate

All procedures in this work were carried out following the principles expressed in the Declaration of Helsinki, as well as in all the other applicable international, national, and/or institutional guidelines for the use of samples and data and have been approved by the Comité de Ética de la Investigación (CEIm) at Hospital Clínico Universitario Virgen de la Arrixaca (protocol number 2020-10-12-HCUVA – Effects of aging in the susceptibility to SARS-CoV-2). In all cases, the parents or legal guardians of the children signed informed consents accepting that the saliva samples were used for research.

619

It is made available under a CC-BY-NC-ND 4.0 International license .

### 620 **Competing interests**

621 The authors declare no competing interests.

622

623

It is made available under a CC-BY-NC-ND 4.0 International license .

### 624 Figure legends

Figure 1. Sample overview using PCA and salivary biomarker levels. A Using the levels of 625 the 13 salivary biomarkers included in this study measured in the 105 saliva samples as input, the 626 data were linearly transformed and visualized in two-dimensional space. Each sample is 627 628 represented by one dot, and colored and shaped according to the group to which it belongs. The percentage of the variance of the original data explained by each of the two principal components 629 is indicated in the axis labels. The 90% confidence data ellipses are shown for each group. B-E 630 Violin plots showing the levels of the 13 biomarkers included in this study in saliva of children 631 with long COVID and controls. Salivary biomarkers have been grouped according to the 632 633 information they provide as indicated. Each sample is represented by one dot. P values were calculated using Student's t-test. ns, not significant; \*P < 0.05, \*\*P < 0.01, and \*\*\*P < 0.001. 634

635

Figure 2. Correlations between the salivary biomarkers measured in this work. Diagrams showing the correlations between all the possible salivary biomarker pairs according to the Pearson correlation coefficients, using the salivary biomarker levels of all the children included in this study (A), only of control children (B), or only of children with long COVID (C). Each cell of the grid refers to the correlation between the two biomarkers faced. The circle sizes are proportional to the strength of the correlations, while the circle colors show the values of the Pearson correlation coefficients according to the legend. Asterisks denote statistically significant correlations.

643

Figure 3. Checking the utility of the salivary biomarkers to discriminate between children 644 with long COVID and controls, as well as between children with long COVID who present a 645 severe form of the disease and those others with mild symptoms. A, C, D PCAs using as input 646 the levels of the biomarkers TOS, ADA2, total proteins, and AOPP measured in the 105 saliva 647 samples included in this study (A), the levels of the 13 biomarkers included in this study measured 648 in the 49 saliva samples from children with long COVID (C), and the levels of the biomarkers 649 total proteins and ADA1 measured in the 49 saliva samples from children with long COVID (**D**). 650 In all three cases, the data were linearly transformed and visualized in two-dimensional space. 651 652 Each sample is represented by one dot, and colored and shaped according to the group to which it

It is made available under a CC-BY-NC-ND 4.0 International license .

belongs. The percentage of the variance of the original data explained by each of the two principal components is indicated in the axis labels. The 90% confidence data ellipses are shown for each group. **B**, **E** ROC curves to assess the predictive value of the levels of the salivary biomarkers TOS, ADA2, total proteins, and AOPP to discriminate between children with long COVID and controls (**B**), and of the salivary biomarkers total proteins and ADA1 to discriminate between children with long COVID who present a severe form of the disease and those others with mild symptoms (**E**).

Figure 4. Correlations between the salivary biomarkers and the demographic/clinical variables in children with long COVID. Diagram showing the correlations between the salivary biomarkers and the demographic/clinical variables in children with long COVID, according to the Pearson correlation coefficients. Each intersection of the grid refers to the correlation between the two variables faced. The circle sizes show the strength of the correlations according to their *P* values, while the circle colors refer to the statistical significance of the correlations considering a *P* value  $\leq 0.05$  as the threshold.

- 668
- 669
- 670
- 671
- 672
- 673
- 674
- 675
- 676
- 677

678

<sup>660</sup> 

### 679 **References**

680 (1999). "IFCC methods for measurement of catalytic concentration of enzymes. Part 9. IFCC method for

alpha-amylase [1,4-alpha-D-glucan 4-glucanohydrolase, EC 3.2.1.1]. International Federation of Clinical
 Chemistry." Clin Chim Acta 281(1-2): S5-39.

- 683 Al-Aly, Z., Y. Xie and B. Bowe (2021). "High-dimensional characterization of post-acute sequelae of COVID-684 19." Nature **594**(7862): 259-264.
- 685 Baganha, M. F., A. Pêgo, M. A. Lima, E. V. Gaspar and A. R. Cordeiro (1990). "Serum and pleural adenosine 686 deaminase. Correlation with lymphocytic populations." <u>Chest</u> **97**(3): 605-610.
- 687 Baig, A. M. (2021). "Chronic COVID syndrome: Need for an appropriate medical terminology for long-688 COVID and COVID long-haulers." J Med Virol **93**(5): 2555-2556.
- Barranco, T., C. P. Rubio, A. Tvarijonaviciute, M. Rubio, E. Damia, E. Lamy, R. Cugat, J. J. Cerón, F. Tecles
  and D. Escribano (2019). "Changes of salivary biomarkers under different storage conditions: effects of
  temperature and length of storage." Biochem Med (Zagreb) 29(1): 010706.
- 692 Behan, P. O. and W. M. Behan (1988). "Postviral fatigue syndrome." Crit Rev Neurobiol 4(2): 157-178.
- 693 Benzie, I. F. and J. J. Strain (1996). "The ferric reducing ability of plasma (FRAP) as a measure of 694 "antioxidant power": the FRAP assay." <u>Anal Biochem</u> **239**(1): 70-76.
- Blomberg, B., K. G. Mohn, K. A. Brokstad, F. Zhou, D. W. Linchausen, B. A. Hansen, S. Lartey, T. B. Onyango,
- K. Kuwelker, M. Sævik, H. Bartsch, C. Tøndel, B. R. Kittang, R. J. Cox, N. Langeland and B. C.-R. Group (2021).
  "Long COVID in a prospective cohort of home-isolated patients." Nat Med 27(9): 1607-1613.
- Calis, M., F. Ates, C. Yazici, K. Kose, M. Kirnap, M. Demir, M. Borlu and C. Evereklioglu (2005). "Adenosine
  deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine
  deaminase levels in patients with Behçet's disease." Rheumatol Int 25(6): 452-456.
- 701 Cesarone, M. R., G. Belcaro, M. Carratelli, U. Cornelli, M. T. De Sanctis, L. Incandela, A. Barsotti, R.
- Terranova and A. Nicolaides (1999). "A simple test to monitor oxidative stress." <u>Int Angiol</u> 18(2): 127-130.
  Chua, P. E. Y., S. U. Shah, H. Gui, J. Koh, J. Somani and J. Pang (2021). "Epidemiological and clinical characteristics of non-severe and severe pediatric and adult COVID-19 patients across different geographical regions in the early phase of pandemic: a systematic review and meta-analysis of observational studies." <u>J Investig Med</u> 69(7): 1287-1296.
- 707 Contreras-Aguilar, M. D., A. Tvarijonaviciute, I. Monkeviciene, M. Martín-Cuervo, L. G. González-Arostegui,
- L. Franco-Martínez, J. J. Cerón, F. Tecles and D. Escribano (2020). "Characterization of total adenosine
   deaminase activity (ADA) and its isoenzymes in saliva and serum in health and inflammatory conditions in
   four different energies: an analytical and clinical validation pilot study." BMC Vet Bos 16(1): 284
- four different species: an analytical and clinical validation pilot study." <u>BMC Vet Res</u> **16**(1): 384.
- Cucinotta, D. and M. Vanelli (2020). "WHO Declares COVID-19 a Pandemic." <u>Acta Biomed</u> **91**(1): 157-160.
- Dao, T. L., V. T. Hoang, N. N. Nguyen, J. Delerce, H. Chaudet, A. Levasseur, J. C. Lagier, D. Raoult, P. Colson
- and P. Gautret (2021). "Clinical outcomes in COVID-19 patients infected with different SARS-CoV-2
- variants in Marseille, France." <u>Clin Microbiol Infect</u> **27**(10): 1516.e1511-1516.e1516.
- 715 Davis, H. E., G. S. Assaf, L. McCorkell, H. Wei, R. J. Low, Y. Re'em, S. Redfield, J. P. Austin and A. Akrami
- (2021). "Characterizing long COVID in an international cohort: 7 months of symptoms and their impact."
   EClinicalMedicine **38**: 101019.
- 717 <u>EClinicaliviedicine</u> **38**: 101019.
- Deneva, T., Y. Ianakiev and O. Boykinova (2022). "Salivary mental stress biomarkers in COVID-19 patients."
   <u>Front Med (Lausanne)</u> 9: 999215.
- 720 Ebrahimi-Rad, M., S. Khatami, S. Ansari, S. Jalylfar, S. Valadbeigi and R. Saghiri (2018). "Adenosine
- 721 Deaminase 1 as a Biomarker for Diagnosis and Monitoring of Patients with Acute Lymphoblastic
- 722 Leukemia." J Med Biochem **37**(2): 128-133.
- 723 Efroymson and MA (1960). Multiple
- regression analysis. . <u>Mathematical methods for digital computers</u>. Ralston and W. H. A. New York, Wiley.

It is made available under a CC-BY-NC-ND 4.0 International license .

- Erel, O. (2005). "A new automated colorimetric method for measuring total oxidant status." <u>Clin Biochem</u>
- 726 **38**(12): 1103-1111.
- Fainardi, V., A. Meoli, G. Chiopris, M. Motta, K. Skenderaj, R. Grandinetti, A. Bergomi, F. Antodaro, S. Zona
  and S. Esposito (2022). "Long COVID in Children and Adolescents." Life (Basel) 12(2).
- 729 Fawcett, T. (2006). "An introduction to ROC analysis." Pattern Recognition Letters **27**(8).
- 730 Franco-Martínez, L., J. J. Cerón, M. R. Vicente-Romero, E. Bernal, A. Torres Cantero, F. Tecles, C. Sánchez
- 731 Resalt, M. Martínez, A. Tvarijonaviciute and S. Martínez-Subiela (2021). "Salivary Ferritin Changes in
- 732 Patients with COVID-19." Int J Environ Res Public Health **19**(1).
- 733 Franco-Martínez, L., F. Tecles, A. Torres-Cantero, E. Bernal, I. San Lázaro, M. J. Alcaraz, M. R. Vicente-
- 734 Romero, E. Lamy, C. Sánchez-Resalt, C. P. Rubio, A. Tvarijonaviciute, S. Martínez-Subiela and J. J. Cerón
- 735 (2021). "Analytical validation of an automated assay for the measurement of adenosine deaminase (ADA)
- and its isoenzymes in saliva and a pilot evaluation of their changes in patients with SARS-CoV-2 infection."
   Clin Chem Lab Med **59**(9): 1592-1599.
- 738 Franco-Martínez, L., A. Tvarijonaviciute, S. Martínez-Subiela, G. Márquez, N. Martínez Díaz, R. Cugat, J. J.
- 739 Cerón and P. Jiménez-Reyes (2019). "Changes in lactate, ferritin, and uric acid in saliva after repeated
- explosive effort sequences." <u>J Sports Med Phys Fitness</u> **59**(6): 902-909.
- Gandhi, R. T., J. B. Lynch and C. Del Rio (2020). "Mild or Moderate Covid-19." <u>N Engl J Med</u> 383(18): 17571766.
- 743 Gonzalez-Aumatell, A., M. V. Bovo, C. Carreras-Abad, S. Cuso-Perez, E. Domenech Marsal, R. Coll-
- 744 Fernandez, A. Goicoechea Calvo, M. Giralt-Lopez, A. Ensenat Cantallops, S. Moron-Lopez, J. Martinez-
- Picado, P. Sol Ventura, C. Rodrigo and M. Mendez Hernandez (2022). "Social, Academic, and Health Status
- 746 Impact of Long COVID on Children and Young People: An Observational, Descriptive, and Longitudinal
- 747 Cohort Study." <u>Children (Basel)</u> **9**(11).
- Grant, M. C., L. Geoghegan, M. Arbyn, Z. Mohammed, L. McGuinness, E. L. Clarke and R. G. Wade (2020).
- The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19):
- A systematic review and meta-analysis of 148 studies from 9 countries." <u>PLoS One</u> **15**(6): e0234765.
- Greenhalgh, T., M. Knight, C. A'Court, M. Buxton and L. Husain (2020). "Management of post-acute covid19 in primary care." <u>BMJ</u> **370**: m3026.
- H, W. (2016). ggplot2: Elegant Graphics for Data Analysis. New York, NY, USA, Springer.
- Inui, S., A. Fujikawa, W. Gonoi, S. Kawano, K. Sakurai, Y. Uchida, M. Ishida and O. Abe (2022). "Comparison
   of CT findings of coronavirus disease 2019 (COVID-19) pneumonia caused by different major variants." Jpn
   J Radiol 40(12): 1246-1256.
- 757 Jedrzejewska, A., A. Kawecka, A. Braczko, M. Romanowska-Kocejko, K. Stawarska, M. Deptuła, M.
- 758 Zawrzykraj, M. Franczak, O. Krol, G. Harasim, I. Walczak, M. Pikuła, M. Hellmann and B. Kutryb-Zając
- 759 (2023). "Changes in Adenosine Deaminase Activity and Endothelial Dysfunction after Mild Coronavirus
- 760 Disease-2019." Int J Mol Sci **24**(17).
- Jezova, D., J. Trebaticka, K. Buzgoova, Z. Durackova and N. Hlavacova (2020). "Lower activity of salivary
  alpha-amylase in youths with depression." <u>Stress</u> 23(6): 688-693.
- Lee, Y. H. and D. T. Wong (2009). "Saliva: an emerging biofluid for early detection of diseases." <u>Am J Dent</u> **22**(4): 241-248.
- Leviner, S. (2021). "Recognizing the Clinical Sequelae of COVID-19 in Adults: COVID-19 Long-Haulers." J
   <u>Nurse Pract</u> 17(8): 946-949.
- Copez-Leon, S., T. Wegman-Ostrosky, N. C. Ayuzo Del Valle, C. Perelman, R. Sepulveda, P. A. Rebolledo, A.
- 768 Cuapio and S. Villapol (2022). "Long-COVID in children and adolescents: a systematic review and meta-769 analyses." <u>Sci Rep</u> **12**(1): 9950.
- TTO Lopez-Leon, S., T. Wegman-Ostrosky, C. Perelman, R. Sepulveda, P. A. Rebolledo, A. Cuapio and S. Villapol
- 771 (2021). "More than 50 long-term effects of COVID-19: a systematic review and meta-analysis." Sci Rep
- 772 **11**(1): 16144.

- 773 MacDermott, R. P., G. L. Tritsch and J. F. Formeister (1980). "Adenosine deaminase and nucleoside
- phosphorylase activities in normal human blood mononuclear cell subpopulations." <u>Clin Exp Immunol</u>
   42(2): 303-307.
- 776 Martínez-Subiela, S., L. Franco-Martínez, C. P. Rubio, A. Muñoz-Prieto, A. Torres-Cantero, F. Tecles, C.
- 777 Sánchez-Resalt, J. J. Cerón and A. Tvarijonaviciute (2022). "Measurement of anti SARS-CoV-2 RBD IgG in
- saliva: validation of a highly sensitive assay and effects of the sampling collection method and correction
- 779 by protein." <u>Clin Chem Lab Med</u> **60**(10): 1683-1689.
- 780 Masters, J. M., A. J. Noyce, T. T. Warner, G. Giovannoni and G. B. Proctor (2015). "Elevated salivary protein
- in Parkinson's disease and salivary DJ-1 as a potential marker of disease severity." <u>Parkinsonism Relat</u>
   <u>Disord</u> 21(10): 1251-1255.
- Matsuura, T., R. Takimura, M. Yamaguchi and M. Ichinose (2012). "Estimation of restraint stress in rats
  using salivary amylase activity." J Physiol Sci 62(5): 421-427.
- Mishra, O. P., B. L. Gupta, Z. Ali, G. Nath and L. Chandra (1994). "Adenosine deaminase activity in typhoid
   fever." <u>Indian Pediatr</u> **31**(11): 1379-1384.
- Nater, U. M. and N. Rohleder (2009). "Salivary alpha-amylase as a non-invasive biomarker for the sympathetic nervous system: current state of research." <u>Psychoneuroendocrinology</u> **34**(4): 486-496.
- 789 Pajcin, M., S. Banks, J. M. White, J. Dorrian, G. M. Paech, C. Grant, K. Johnson, K. Tooley, J. Fidock, G. H.
- 790 Kamimori and C. B. Della Vedova (2017). "Decreased salivary alpha-amylase levels are associated with 791 performance deficits during sleep loss." <u>Psychoneuroendocrinology</u> **78**: 131-141.
- Robin, X., N. Turck, A. Hainard, N. Tiberti, F. Lisacek, J. C. Sanchez and M. Müller (2011). "pROC: an opensource package for R and S+ to analyze and compare ROC curves." <u>BMC Bioinformatics</u> 12: 77.
- Rohleder, N. and U. M. Nater (2009). "Determinants of salivary alpha-amylase in humans and methodological considerations." <u>Psychoneuroendocrinology</u> **34**(4): 469-485.
- Rubio, C. P. and J. J. Cerón (2021). "Spectrophotometric assays for evaluation of Reactive Oxygen Species
  (ROS) in serum: general concepts and applications in dogs and humans." <u>BMC Vet Res</u> 17(1): 226.
- S Lê , J Josse and F. Husson (2008). "FactoMineR: an R package for multivariate analysis." <u>Journal of</u>
   <u>statistical software</u> 25(1): 1–18.
- Santosh, U. P., G. S. Renukananda and S. Abhilash (2016). "Role of Adenosine Deaminase in Common
   Chronic ENT Infections." J Clin Diagn Res 10(3): MC01-02.
- 802 Sari, R. A., S. Taysi, O. Yilmaz and N. Bakan (2003). "Correlation of serum levels of adenosine deaminase
- activity and its isoenzymes with disease activity in rheumatoid arthritis." <u>Clin Exp Rheumatol</u> **21**(1): 87-90.
- Shaila, M., G. P. Pai and P. Shetty (2013). "Salivary protein concentration, flow rate, buffer capacity and pH estimation: A comparative study among young and elderly subjects, both normal and with gingivitis
- and periodontitis." <u>J Indian Soc Periodontol</u> **17**(1): 42-46.
- Sharif, K., V. Vieira Borba, G. Zandman-Goddard and Y. Shoenfeld (2018). "Eppur Si Muove: ferritin is essential in modulating inflammation." <u>Clin Exp Immunol</u> **191**(2): 149-150.
- Soriano, J. B., S. Murthy, J. C. Marshall, P. Relan, J. V. Diaz and W. C. C. D. W. G. o. P.-C.-. Condition (2022).
- 810 "A clinical case definition of post-COVID-19 condition by a Delphi consensus." <u>Lancet Infect Dis</u> 22(4):
  811 e102-e107.
- Sullivan, J. L., W. R. Osborne and R. J. Wedgewood (1977). "Adenosine deaminase activity in lymphocytes."
   <u>Br J Haematol</u> 37(1): 157-158.
- 814 Taquet, M., Q. Dercon, S. Luciano, J. R. Geddes, M. Husain and P. J. Harrison (2021). "Incidence, co-
- 815 occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 816 survivors of COVID-19." PLoS Med **18**(9): e1003773.
- 817 Tecles, F., M. Fuentes-Rubio, A. Tvarijonaviciute, S. Martínez-Subiela, J. Fatjó and J. J. Cerón (2014).
- 818 "Assessment of stress associated with an oral public speech in veterinary students by salivary biomarkers."
- 819 <u>J Vet Med Educ</u> **41**(1): 37-43.

- 820 Tvarijonaviciute, A., C. Aznar-Cayuela, C. P. Rubio, J. J. Ceron and P. López-Jornet (2017). "Evaluation of
- salivary oxidate stress biomarkers, nitric oxide and C-reactive protein in patients with oral lichen planus
- and burning mouth syndrome." <u>J Oral Pathol Med</u> **46**(5): 387-392.
- Tvarijonaviciute, A., C. Aznar-Cayuela, C. P. Rubio, F. Tecles, J. J. Ceron and P. López-Jornet (2018). "Salivary
- Antioxidant Status in Patients with Oral Lichen Planus: Correlation with Clinical Signs and Evolution during
   Treatment with." Biomed Res Int **2018**: 5187549.
- Tyrkalska, S. D., A. Martinez-Lopez, A. B. Arroyo, F. J. Martinez-Morcillo, S. Candel, D. Garcia-Moreno, P.
- 827 Mesa-Del-Castillo, M. L. Cayuela and V. Mulero (2022). "Differential proinflammatory activities of Spike 828 proteins of SARS-CoV-2 variants of concern." <u>Sci Adv</u> **8**(37): eabo0732.
- Vargas-Vargas, M. and C. Cortés-Rojo (2020). "Ferritin levels and COVID-19." <u>Rev Panam Salud Publica</u> **44**: 830 e72.
- Vijayamahantesh, A. Amit, M. R. Dikhit, R. K. Pandey, K. Singh, R. Mishra, V. N. Das, P. Das and S. Bimal
- 832 (2016). "Elevated Serum ADA Activity as a Marker for Diagnosis and Prognosis of Visceral Leishmaniasis 833 and Post Kala-Azar Dermal Leishmaniasis in Indian Patients." <u>PLoS One</u> **11**(5): e0154117.
- Vona, R., L. Pallotta, M. Cappelletti, C. Severi and P. Matarrese (2021). "The Impact of Oxidative Stress in
  Human Pathology: Focus on Gastrointestinal Disorders." <u>Antioxidants (Basel)</u> 10(2).
- 836 Wiersinga, W. J., A. Rhodes, A. C. Cheng, S. J. Peacock and H. C. Prescott (2020). "Pathophysiology,
- 837 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review." JAMA
- **324**(8): 782-793.
- Witko-Sarsat, V., M. Friedlander, C. Capeillère-Blandin, T. Nguyen-Khoa, A. T. Nguyen, J. Zingraff, P.
- Jungers and B. Descamps-Latscha (1996). "Advanced oxidation protein products as a novel marker of
   oxidative stress in uremia." <u>Kidney Int</u> **49**(5): 1304-1313.
- Wolf, J. M., E. Nicholls and E. Chen (2008). "Chronic stress, salivary cortisol, and alpha-amylase in children
  with asthma and healthy children." <u>Biol Psychol</u> **78**(1): 20-28.
- Yelin, D., E. Wirtheim, P. Vetter, A. C. Kalil, J. Bruchfeld, M. Runold, G. Guaraldi, C. Mussini, C. Gudiol, M.
- Pujol, A. Bandera, L. Scudeller, M. Paul, L. Kaiser and L. Leibovici (2020). "Long-term consequences of COVID-19: research needs." <u>Lancet Infect Dis</u> **20**(10): 1115-1117.
- Yoon, S. H., J. H. Lee and B. N. Kim (2023). "Chest CT Findings in Hospitalized Patients with SARS-CoV-2:
  Delta versus Omicron Variants." <u>Radiology</u> **306**(1): 252-260.
- Yoshizawa, J. M., C. A. Schafer, J. J. Schafer, J. J. Farrell, B. J. Paster and D. T. Wong (2013). "Salivary
  biomarkers: toward future clinical and diagnostic utilities." <u>Clin Microbiol Rev</u> 26(4): 781-791.
- Zandman-Goddard, G. and Y. Shoenfeld (2007). "Ferritin in autoimmune diseases." <u>Autoimmun Rev</u> 6(7):
  457-463.
- Zhang, L., H. Xiao and D. T. Wong (2009). "Salivary biomarkers for clinical applications." <u>Mol Diagn Ther</u> **13**(4): 245-259.
- Zhu, N., D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, P. Niu, F. Zhan, X. Ma,
- D. Wang, W. Xu, G. Wu, G. F. Gao, W. Tan and C. N. C. I. a. R. Team (2020). "A Novel Coronavirus from
- Patients with Pneumonia in China, 2019." <u>N Engl J Med</u> **382**(8): 727-733.

858





# D: Stress levels



# E: General homeostatic status







Long COVID

Control

Long COVID

## Figure 2



It is made available under a CC-BY-NC-ND 4.0 International license

B















Fatigue test -Respiratory symptoms -CNS symptoms -Cardiovascular symptoms -Interruption of sports activity -Weight loss -Brain fog -Insomnia -Long COVID severity -Gender -Relatives with long COVID -Asthma -Altered school attendance -Atopy

Reduced school performance -Previous psychiatric disorder -Interruption of extracurricular activities s://doi.ora/10.1101/2023.12.17.23300097; this version posted December 18, 2023. The copyright holder for this view) is the author/funder, who has granted medRxiv a license to display the prep It is made available under a CC-BY-NC-ND 4.0 International licer

# Figure 4





# *P* value

- 0.05
- 0.025
- 0.016

# Significance

- <=0.05
- >0.05

Table 1. LongsGQV/ID patient demographics and clinical sinformation	

Number of patients	49
Average diagnosis age (range)	13.3 (9-18)
Female sex (%)	34 (69.4)
Mild long COVID (%)	35 (71.4)
Severe long COVID (%)	14 (28.6)
Relatives with long COVID (%)	15 (30.6)
Previous psychiatric disorder (%)	5 (10.2)
Atopy (%)	7 (14.3)
Asthma (%)	4 (8.2)
Fatigue test with 'high' or 'very high' result (%)	22 (44.9)
CNS symptoms (%)	39 (79.6)
Brain fog (%)	29 (59.2)
Weight loss (%)	11 (22.4)
Respiratory symptoms (%)	29 (59.2)
Cardiovascular symptoms (%)	32 (65.3)
Insomnia (%)	23 (46.9)
Altered school attendance (%)	14 (28.6)
Reduced school performance (%)	22 (44.9)
Interruption of extracurricular activities (%)	24 (49.0)
Interruption of sports activity (%)	26 (53.1)